Omega-3-acid ethyl esters A (Omtryg)
Small molecule
Also known as AKR-963
Evidence outlook
Approved: Severe Hypertriglyceridemia, Hypertriglyceridemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Review complete: no registered study met the criteria for featured evidence in this indication.
No registered study from this product's approval programme in this use was found on ClinicalTrials.gov.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Competitive landscape
This drug's own stage for Hypertriglyceridemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Omega-3-Acid Ethyl Esters A (Omtryg): this drug | Approved | Small molecule | Triglyceride synthesis / VLDL | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Olezarsen (Tryngolza) | Phase 3 | RNA / oligonucleotide | APOC3 | Reliable signal | NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001). | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Reliable signal | NCT04998981: n=344 randomized (of 353 enrolled per CT.gov). % change in fasting TG from baseline at Week 12: -34.1% (pemafibrate 0.2mg/d), -44.0% (pemafibrate 0.4mg/d), -30.5% (fenofibrate 200mg/d), +6.5% (placebo); 0.4mg/d vs placebo p<0.0001, vs fenofibrate p=0.0083. | |
| Plozasiran (Redemplo) | Phase 3 | RNA / oligonucleotide | APOC3 | Partial signal | NCT06347003: Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22). | |
| Pravafenix | Phase 3(overall) | Small molecule | HMG-CoA reductase / PPAR-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Saroglitazar (Lipaglyn) | Phase 3(overall) | Small molecule | PPAR-alpha/PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication | |
| BW-00112 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| EDP167 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-7249 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ION775 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| MAR001 | Phase 2 | Monoclonal antibody | ANGPTL4 | Weak signal | Featured results are safety only in this race | |
| RBD5044 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| SYH2070 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| Tipelukast | Phase 2 | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenase | Weak signal | NCT02681055: Primary 1, cholesterol efflux capacity change from baseline to week 12: mean -0.013 (SD 0.1022) percentage of cholesterol. Primary 2, serum triglyceride change from baseline to week 8: mean -21.67 (SD 27.89) mg/dL. Single arm (n=19), no comparator; CT.gov posted results. | |
| TLC-2716 | Phase 2 | Small molecule | Liver X receptor (LXR) | not yet graded | No reviewed efficacy summary in this indication | |
| JMT202 | Phase 1/2 | Monoclonal antibody | β-Klotho (KLB) | not yet graded | No reviewed efficacy summary in this indication | |
| RN0361 | Phase 1/2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-APOC3 | Phase 1(overall) | RNA / oligonucleotide | Apolipoprotein C-III (APOC3) | not yet graded | No reviewed efficacy summary in this indication | |
| ISH0688 | Phase 1 | Protein / enzyme therapeutic | FGF21 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Kylo-12 | Phase 1 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| VERVE-201 | Phase 1 | Gene therapy / editing | ANGPTL3 gene (hepatocyte genomic DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.